Remicade (Infliximab) in Pregnancy: FDA Category B – Risks & Considerations
FDA Pregnancy Category B (no human risk in controlled studies; animal studies show no fetal harm).
Clinical Guidance
- Use only if clearly needed; benefit > risk.
- Consider discontinuation if disease controlled without it.
- If continued, time infusions to minimize placental transfer in 3rd trimester (IgG crosses increasingly after 30 weeks).
- Live vaccines (rotavirus, BCG) deferred in infant until 6–12 months if exposed in utero.
Breastfeeding
Infliximab present in milk at low levels; generally considered compatible, but discuss with provider.
Shared decision-making with rheumatologist and OB is essential.
Pregnancy & Health - Related Articles
- Pawpaw During Pregnancy: Safety & Benefits for Moms-to-Be
- Early Pregnancy Mood Swings: What to Expect
- Pregnancy Symptoms With Negative Test: Causes and Next Steps
- Creamy White Discharge After Ovulation: Pregnancy Sign or Normal Cycle Variation?
- Early Pregnancy Symptoms: First Weeks After Conception
- Understanding Aneuploidy Risk: Causes, Symptoms & Prenatal Screening
- Multiple Cesarean Deliveries: Risks and Considerations for Future Pregnancies
